Lovenox (enoxaparin sodium)

April 3, 2002

Audience: Healthcare Professionals

FDA and Aventis strengthened the WARNINGS and PRECAUTIONS sections of the Lovenox prescribing information to inform healthcare professionals that the use of Lovenox Injection is not recommended for thromboprophylaxis in patients with prosthetic heart valves. New postmarketing safety information concerning congenital anomalies and non-teratogenic effects on pregnant women and fetuses are described.

[Feb 28, 2002 Letter - Aventis]
[July, 2001 Revised Label - Aventis] Changes highlighted

View comments

Questions about Atrial Fibrillation? Get answers from our expert. Watch Video

Close
Hide
(web5)